Take­da drops $300M cash to kick off $1B RNAi al­liance with Ar­row­head, shoot­ing for first-in-class rare dis­ease drug

Twelve years ago, Take­da be­came the first ma­jor Asian phar­ma com­pa­ny to buy in­to Al­ny­lam’s pi­o­neer­ing RNAi plat­form with a land­mark $1 bil­lion al­liance. Two FDA ap­provals and a slew of new deals for the field lat­er, the Japan­ese drug­mak­er is mak­ing a new $1.04 bil­lion bet on a rare dis­ease pro­gram from a J&J-part­nered RNAi play­er.

Ar­row­head is grab­bing $300 mil­lion of that up­front in ex­change for co-de­vel­op­ment and co-com­mer­cial­iza­tion rights of ARO-AAT, which is de­signed to knock down the pro­duc­tion of mu­tant al­pha-1 an­tit­rypsin pro­teins in pa­tients with AAT-as­so­ci­at­ed liv­er dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.